Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine

In a modified sample of 310 patients, desvenlafaxine treatment was associated with significantly greater improvement in functional outcomes at 12 weeks.

• Functional outcomes assessed included work functioning and overall disability, measured using validated scales.
• Desvenlafaxine-treated patients showed improvements in specific subgroups, including responders, nonanxious individuals, and those with normal energy levels.
• Early improvement in depressive symptoms at week 2 was predictive of better functional outcomes at week 12.
• The analysis was based on data from a double-blind, placebo-controlled trial involving 427 patients.
• Improvements in functional outcomes were not observed in the overall intent-to-treat sample.

AI simplified